Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.58 |
| ▸ | POLB | P06746 | 1/20 | 0.58 |
| ▸ | RAB9A | P51151 | 2/20 | 0.54 |
| ▸ | MEN1 | O00255 | 1/20 | 0.54 |
| ▸ | NPC1 | O15118 | 1/20 | 0.54 |
| ▸ | CASP3 | P42574 | 1/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.54 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.54 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.54 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.54 |
| ▸ | TRPV1 | Q8NER1 | 7/20 | 0.53 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.51 |
| ▸ | CTSK | P43235 | 1/20 | 0.51 |
| ▸ | FAAH | O00519 | 1/20 | 0.50 |
| ▸ | AAK1 | Q2M2I8 | 2/20 | 0.49 |
| ▸ | HTT | P42858 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26741144 | 0.86 | RAB9A (0.56) | LMNAPOLBRAB9AMEN1NPC1 | |
| SCHEMBL26741145 | 0.86 | RAB9A (0.56) | LMNAPOLBRAB9AMEN1NPC1 | |
| SCHEMBL9267426 | 0.83 | MEN1 (0.61) | MEN1KMT2ACHEK1 | |
| SCHEMBL5264997 | 0.83 | MEN1 (0.61) | MEN1KMT2ACHEK1 | |
| SCHEMBL21755225 | 0.80 | LMNA (0.56) | LMNAPOLBRAB9AMEN1NPC1 | |
| SCHEMBL21210988 | 0.80 | LMNA (0.64) | LMNAPOLBRAB9AMEN1NPC1 | |
| SCHEMBL24688163 | 0.79 | LMNA (0.62) | LMNAPOLBRAB9AMEN1NPC1 | |
| SCHEMBL24767438 | 0.79 | HSD17B10 (0.59) | LMNAPOLBRAB9AMEN1NPC1 | |
| SCHEMBL22939497 | 0.78 | HTT (0.61) | LMNARAB9AMEN1NPC1KMT2A | |
| SCHEMBL1800442 | 0.78 | HTT (0.61) | LMNARAB9AMEN1NPC1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120178783-A1 | HDAC INHIBITORS | LIXTE BIOTECHNOLOGY, INC. | 2012-07-12 | — | — | US | disclosed |
| US-8143445-B2 | HDAC inhibitors | LIXTE BIOTECHNOLOGY, INC. (US) | 2012-03-27 | — | — | US | disclosed |
| WO-2009045440-A1 | HDAC INHIBITORS | LIXTE BIOTECHNOLOGY HOLDINGS, INC. (US) | 2009-04-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120178783-A1 | HDAC INHIBITORS | HDAC3, HDAC4, HDAC7 | LMNA 2276/4885POLB 3033/4885RAB9A 3674/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.